FDA Approves Allecra’s Exblifep, Giving Headstart Over Competition in Complicated Urinary Tract Infections

- The Food and Drug Administration (FDA) has granted approval to Allecra Therapeutics' Exblifep (cefepime/enmetazobactam), a small molecule drug designed to treat complicated urinary tract infections (UTIs).
- Exblifep is part of the class of drugs known as beta-lactamase inhibitors, which are used against gram-negative bacterial infections.
- The approval provides a headstart for Allecra over competing products targeting similar indications, such as Taniborbactam, another beta-lactamase inhibitor currently undergoing clinical trials.
- Clinical studies have been conducted with positive outcomes, including Phase 2 evaluations for various Gram-Negative Bacterial Infections.